pluri-biotech.com (PLUR) - Koefisien utang jangka dawa marang modal

Pluri - logo grafis emiten PLUR

A strong team of Israeli placental technology scientists provides the intellectual potential of Pluri Inc. (PLUR). The ratio of long-term loans to equity visualizes the financial dynamics, where the value 0.00 captures the metric level. The business foundation is a modern plant in Israel with an autonomous power supply. However, the lack of recurring revenue due to a focus on clinical trials makes the company dependent on external financing.

pluri-biotech.com (PLUR): Utang jangka dawa marang ekuitas saka 28.04.2023 nganti 29.10.2026
Produk mawa merek Pluristem Therapeutics

A fundamental stress test of assets requires an assessment of the financing structure's resilience. Pluri Inc. is currently undergoing a business transformation phase as it develops sales markets for cellular technologies. The long-term debt-to-equity ratio determines the degree of financial leverage and dependence on creditors. By analyzing changes in long-term debt relative to equity, an investor can see the balance between borrowed capital and internal reserves. A low debt load confirms the business's safety during the current period of losses.

Analisis perusahaan pesaing

Ascendis Pharma AS - Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal MDGL|CORT (Corcept Therapeutics Corp) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal RYTM (Rhythm Pharmaceuticals)|Utang jangka dawa marang modal akerotx.com AKRO|MTSR - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal MLTX (MoonLake Immunotherapeutics AG)|Crinetics Pharma (CRNX) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Utang jangka dawa marang modal|Utang jangka dawa marang modal amicusrx.com|Rasio utang jangka dawa marang ekuitas ETNB (89bio)|AGIO (Agios) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Structure Pharma GPCR|MDXG - Rasio utang jangka dawa marang ekuitas|Rezolute, Inc. - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal lexpharma.com|MBX (MBX Biosciences) - Rasio utang jangka dawa marang ekuitas|ALT: Rasio silihan jangka dawa marang modal|AARD (Aardvark Therapeutics Corp) - Utang jangka dawa marang modal|Utang jangka dawa marang modal Sagimet Biosciences Inc|Utang jangka dawa marang modal BIOA|Utang jangka dawa marang ekuitas BMEA (biomeafusion.com)|Utang jangka dawa marang ekuitas Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Kewajiban jangka dawa marang modal|VTVT - Utang jangka dawa marang ekuitas|ATPC: Utang jangka dawa marang ekuitas|SYBX: Utang jangka dawa marang modal|LPCN - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Galecto Corp (GLTO)|Rasio utang jangka dawa marang ekuitas Carmell Therapeutics CTCX|Utang jangka dawa marang ekuitas Lumos Pharma, Inc. LUMO|ONVO (organovo.com) - Kewajiban jangka dawa marang ekuitas|RDUS - Utang jangka dawa marang ekuitas